{"classes":[{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG000","spread":"NA","value":"0.91"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG001","spread":"NA","value":"3.90"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG002","spread":"NA","value":"3.76"},{"groupId":"OG003","spread":"78.94","value":"4.88"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG004","spread":"NA","value":"8.12"},{"groupId":"OG005","spread":"114.63","value":"2.26"},{"groupId":"OG006","spread":"88.47","value":"32.85"},{"groupId":"OG007","spread":"41.92","value":"5.99"},{"groupId":"OG008","spread":"128.56","value":"0.03"},{"groupId":"OG009","spread":"102.35","value":"13.21"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG010","spread":"NA","value":"2.08"},{"groupId":"OG011","spread":"123.78","value":"15.77"},{"groupId":"OG012","spread":"92.05","value":"2.25"},{"groupId":"OG013","spread":"139.74","value":"42.18"},{"groupId":"OG014","spread":"68.62","value":"14.34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"7"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"11"},{"groupId":"OG014","value":"2"}],"units":"Participants"}],"description":"Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 5 mg QD"},{"description":"Participants were administered once daily oral dose of 10 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 10 mg QD"},{"description":"Participants were administered once daily oral dose of 20 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 20 mg QD"},{"description":"Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 30 mg QD MM"},{"description":"Participants were administered once daily oral dose of 40 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 40 mg QD"},{"description":"Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 40 mg QD MM"},{"description":"Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 60 mg QD AML"},{"description":"Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 60 mg QD NHL"},{"description":"Participants with MM were administered once daily oral dose of 60 mg GSK525762.","id":"OG008","title":"Part 1: GSK525762 60 mg QD MM"},{"description":"Participants with AML were administered once daily oral dose of 75 mg GSK525762.","id":"OG009","title":"Part 1: GSK525762 75 mg QD AML"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG010","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants with AML were administered once daily oral dose of 80 mg GSK525762.","id":"OG011","title":"Part 1: GSK525762 80 mg QD AML"},{"description":"Participants with NHL were administered once daily oral dose of 80 mg GSK525762.","id":"OG012","title":"Part 1: GSK525762 80 mg QD NHL"},{"description":"Participants with AML were administered once daily oral dose of 100 mg GSK525762.","id":"OG013","title":"Part 1: GSK525762 100 mg QD AML"},{"description":"Participants with AML were administered once daily oral dose of 120 mg GSK525762.","id":"OG014","title":"Part 1: GSK525762 120 mg QD AML"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Week 2 Day 7: Pre-dose on Days 4, 6 and 7","title":"Part 1: Trough Concentration (Ctau) of GSK525762 Following Repeat Dose Administration","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter (ng/mL)"}